Last updated on February 2017

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure


Brief description of study

The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.

Clinical Study Identifier: NCT02862600

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Heart Metabolics Call Center

Stanford, CA United States
  Connect »

Heart Metabolics Call Center

Indianapolis, IN United States
  Connect »

Heart Metabolics Call Center

Baltimore, MD United States
  Connect »

Heart Metabolics Call Center

Columbus, OH United States
  Connect »

Heart Metabolics Call Center

Portland, OR United States
  Connect »

Heart Metabolics Call Center

Germantown, TN United States
  Connect »

Heart Metabolics Call Center

Salt Lake City, UT United States
  Connect »